The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Mark, Kenneth M. K., Varn, Frederick S., Ung, Matthew H., Qian, Feng, Cheng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414335/
https://www.ncbi.nlm.nih.gov/pubmed/28464832
http://dx.doi.org/10.1186/s12885-017-3297-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414335/
https://www.ncbi.nlm.nih.gov/pubmed/28464832
http://dx.doi.org/10.1186/s12885-017-3297-2

Ejemplares similares